Phaseline

Targets › DYRK1

DYRK1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Apr 2027.

Open in Phaseline: the race on DYRK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Asociación Europea y Latinoamericana SELNET para la Investigación en SarcomasCirtuvivint (SM08502)
CLK1-4 and DYRK1-4 kinase inhibitor
CLK1, CLK2, CLK3, CLK4, DYRK1Phase 2Soft Tissue Sarcoma (STS)Apr 2027

Conditions

Soft Tissue Sarcoma (STS) (1)

Modalities

small molecule (1)

Companies

Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas (1)

Related targets

CLK1 (1) CLK2 (1) CLK3 (1) CLK4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.